Ria Kakkad (Drug Target Review)2023-01-20T15:38:55
A new drug could replace the current standard for treating radioresistance brain cancer by sensitising the cancer cells to radiotherapy.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-21T09:36:00
Contributor Jayson Uffens, Drug Target Review
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-06-24T13:00:00
Sponsored by HUB Organoids
2026-09-01T07:00:00
Sponsored by Promega Corporation
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2026-05-22T07:38:00
Contributor Dr Helen Bright, Drug Target Review
Site powered by Webvision Cloud